By: Max Gelman
NorthLinks Bio, backed by RA Capital with $34M, is advancing HEX17 — an intranasal broad-spectrum viral prophylactic from Pneumagen — into a global Phase 2b protection study.
Max Gelman is a Senior Editor at Endpoints News. He specializes in the intersection of medicine and healthcare, with a keen focus on oncology, immunology, and pharmaceuticals, as well as business and economics within the healthcare system. Max's insights and analyses have been featured in Endpoints News, NewsBreak, and World Wealth Journal.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston


Not enough data
Max Gelman's articles predominantly cover the healthcare and pharmaceutical industry, with a focus on clinical trials, drug development, and medical research. His coverage heavily relies on cited data and press releases from private sector announcements.
Given Max's reliance on data-driven content, he is likely to be receptive to pitches that offer exclusive access to new findings or insights based on extensive data analysis within the healthcare and pharmaceutical sectors. Additionally, providing expert commentary or analysis of trends in biotech, pharmaceuticals, clinical trials or medical research might also capture his interest.
As Max does not have a specified geographic focus but seems to cover global developments in the industry; therefore sources with an international perspective may resonate well with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .